The Department of Veterans Affairs recently completed a randomized controlled-trial aimed to test the efficacy of an interventional pulmonary rehabilitation-structured exercise program for patients with Idiopathic Pulmonary Fibrosis. The incidence and prevalence of Idiopathic Pulmonary Fibrosis (IPF) progressively increases with age, being mostly reflected in older males. Risk factors…
Researchers Report on Rehabilitation Program for Patients with Idiopathic Pulmonary Fibrosis
The University of Alabama at Birmingham recently reacted to news of its inclusion into the Pulmonary Fibrosis Foundation Care Center Network, stating that it is an honor in recognition of their commitment towards patients who suffer from pulmonary fibrosis (PF), and that being an official PFFCC will allow them to…
The Pulmonary Fibrosis Foundation (PFF), a trusted resource for the pulmonary fibrosis (PF) community committed to raising awareness, providing disease education, and funding research for this debilitating disease, has just announced it has accredited a dozen new PFF Care Centers, bringing the total number of centers under the…
Boehringer Ingelheim, a leader in developing treatments for lung diseases, sponsored a phase 2 clinical trial investigating four doses of BIBF 1120 (nintedanib) in patients with idiopathic pulmonary fibrosis. The primary goal of “Safety…
In a recent study entitled “Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis,” a team of researchers show acute exacerbations in idiopathic pulmonary fibrosis are caused by multifactorial cellular responses, including macrophage activation. The study was published in the open access journal…
Pulmonary fibrosis may run in the family, based on the frequent occurrence of this disorder in people who are related, according to an article titled Familial Pulmonary Fibrosis recently published in Revue des Maladies Respiratoires by a group from the Centre de Compétence Maladies Rares Pulmonaires, Hôpital…
The European Commission (EC) has approved Boehringer Ingelheim‘s application for the commercialization of the drug nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF), within the European Union. Under the brand name Ofev, the drug therapy was approved by the EC due to…
A study published this week in The Journal of Molecular Medicine Reports discussed the discovery of biological mechanisms that may have important implications in the future treatment of idiopathic pulmonary fibrosis (IPF). The research was conducted by an international team of collaborating scientists from the University…
Lung Institute has announced the opening of a new clinic located in Scottsdale, Arizona this February, according to a press release. The new facility will become the institute’s third center to open in the United States that is focused on treatments using stem cells, joining a center in Tampa and in Nashville.
A new study entitled “PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis” discovered mitochondria PINK1 impaired expression underlies the formation of fibrotic tissue in older patients lungs. The study was published in The Journal of Clinical Investigation. Idiopathic pulmonary fibrosis (IPF) is…
